The pharmacological manipulation of integrins [14,15,18,79,80] or downstream signaling molecules such as FAK or Akt [51,52,53,54,58,59,60,61] has shown some efficacy in preclinical models and may offer promising new avenues to sensitizing cancer cells to anti-RTK therapies. This evidence concerns the gene PTK2 and cancer.